Abstract
We report the case of a male patient in his 40s who was diagnosed as having colorectal cancer harboring both the BRAF V600E mutation and NTRK fusion gene, which have been reported to be mutually exclusive. The patient presented with a history of bloody stool, was diagnosed as having cStage II sigmoid colon cancer, and was scheduled for curative surgery. However, during the surgery, peritoneal dissemination was recognized, and the resection only for sigmoid cancer was performed. The patient was initiated on treatment with capecitabine/L-OHP plus bevacizumab (Bev) as 1st line chemotherapy at another institution.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
